Repligen Corporation (RGEN) Social Stream
REPLIGEN CORP (RGEN) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RGEN.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-02 | 10 | $368 | $240 | $312.555 | $171.63 | 82.11% |
| 2021-12-20 | 10 | $368 | $240 | $315.888 | $171.63 | 84.05% |
| 2022-02-18 | 10 | $368 | $210 | $290.333 | $171.63 | 69.16% |
| 2022-03-01 | 10 | $368 | $210 | $281.444 | $171.63 | 63.98% |
| 2022-04-28 | 10 | $330 | $210 | $257.666 | $171.63 | 50.13% |
| 2022-06-01 | 9 | $330 | $170 | $249.888 | $171.63 | 45.6% |
| 2022-07-20 | 10 | $330 | $170 | $246.888 | $171.63 | 43.85% |
| 2022-08-03 | 10 | $330 | $170 | $248.555 | $171.63 | 44.82% |
| 2022-09-05 | 9 | $330 | $210 | $267.444 | $171.63 | 55.83% |
| 2022-10-23 | 7 | $320 | $210 | $257.125 | $171.63 | 49.81% |
| 2022-10-25 | 8 | $320 | $210 | $257.125 | $171.63 | 49.81% |
| 2022-11-01 | 7 | $320 | $210 | $254.625 | $171.63 | 48.36% |
| 2022-11-02 | 9 | $270 | $200 | $240.5 | $171.63 | 40.13% |
| 2022-12-07 | 9 | $270 | $190 | $232.111 | $171.63 | 35.24% |
| 2023-01-03 | 10 | $270 | $180 | $226.9 | $171.63 | 32.2% |
| 2023-02-02 | 10 | $270 | $180 | $223.9 | $171.63 | 30.46% |
| 2023-02-23 | 10 | $270 | $180 | $215.8 | $171.63 | 25.74% |
| 2023-03-06 | 10 | $250 | $180 | $213.8 | $171.63 | 24.57% |
| 2023-03-07 | 10 | $250 | $180 | $212.8 | $171.63 | 23.99% |
| 2023-04-20 | 11 | $250 | $180 | $214.363 | $171.63 | 24.9% |
| 2023-05-03 | 11 | $250 | $165 | $213 | $171.63 | 24.1% |
| 2023-06-01 | 11 | $240 | $157 | $199.272 | $171.63 | 16.11% |
| 2023-06-28 | 11 | $240 | $157 | $198.363 | $171.63 | 15.58% |
| 2023-07-06 | 11 | $240 | $156 | $196.1 | $171.63 | 14.26% |
| 2023-07-21 | 12 | $240 | $156 | $194.818 | $171.63 | 13.51% |
| 2023-08-01 | 11 | $240 | $156 | $194.818 | $171.63 | 13.51% |
| 2023-08-02 | 11 | $240 | $156 | $193 | $171.63 | 12.45% |
| 2023-08-04 | 11 | $240 | $156 | $193.909 | $171.63 | 12.98% |
| 2023-09-06 | 12 | $240 | $165 | $196.818 | $171.63 | 14.68% |
| 2023-09-13 | 12 | $240 | $165 | $196.454 | $171.63 | 14.46% |
| 2023-10-18 | 13 | $240 | $165 | $197.583 | $171.63 | 15.12% |
| 2023-10-23 | 13 | $240 | $165 | $195.083 | $171.63 | 13.66% |
| 2023-10-31 | 13 | $240 | $158 | $193.25 | $171.63 | 12.6% |
| 2023-11-01 | 13 | $210 | $158 | $186.583 | $171.63 | 8.71% |
| 2023-11-03 | 13 | $210 | $148 | $181.083 | $171.63 | 5.51% |
| 2023-11-07 | 13 | $210 | $148 | $176.5 | $171.63 | 2.84% |
| 2023-12-04 | 13 | $210 | $148 | $175.666 | $171.63 | 2.35% |
| 2023-12-08 | 13 | $210 | $148 | $175.666 | $171.63 | 2.35% |
| 2023-12-18 | 13 | $210 | $148 | $176.5 | $171.63 | 2.84% |
| 2023-12-20 | 13 | $210 | $148 | $178.583 | $171.63 | 4.05% |
| 2023-12-29 | 13 | $210 | $148 | $181.916 | $171.63 | 5.99% |
The Trend in the Analyst Price Target
RGEN's average price target has moved down $128.42 over the prior 23 months.
RGEN reports an average of 19.68% for its upside potential over the past 47 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-05-03 | 11 | 250 | 165 | 213.000 | 163.44 | 30.32% |
| 2023-10-30 | 13 | 240 | 158 | 193.250 | 114.17 | 69.27% |
| 2023-11-17 | 13 | 210 | 148 | 175.666 | 150.60 | 16.64% |
| 2023-11-22 | 13 | 210 | 148 | 175.666 | 160.21 | 9.65% |
| 2023-12-06 | 13 | 210 | 148 | 175.666 | 156.20 | 12.46% |
RGEN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.54 | 9 | 1 | 3 | 0 | 0 | 13 |
The Trend in the Broker Recommendations
Over the past 20 months, RGEN's average broker recommendation rating worsened by 0.32.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RGEN as an investment opportunity.
- REPLIGEN CORP's average analyst price target is higher than 4536.18% of all US stocks.
- REPLIGEN CORP's upside potential (average analyst target price relative to current price) is higher than 1327.78% of Pharmaceutical Products stocks.
- RGEN has a lower variance in analysts' estimates than -1250.36% of Pharmaceutical Products stocks.
- RGEN has a greater number of analysts covering the stock than 3544.11% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to REPLIGEN CORP are DNA, CGC, and TLRY.
View All Top Stocks by Price Target
What is the outlook for RGEN? Use POWR Ratings for clearer insight into price direction.